{
  "ticker": "PAR",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02962191",
  "id": "02962191",
  "pages": 7,
  "price_sensitive": true,
  "date": "20250626",
  "time": "0827",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250626/pdf/06l3tvmhglm9cz.pdf",
  "summary": "**Material Information Summary**  \n\n- **Acquisition Announcement**: Paradigm acquires Proteobioactives Pty Ltd, securing global patent rights for an oral PPS + COX-2 inhibitor combination therapy (Pentacoxib\u2122).  \n  - **Target Markets**: Early-stage osteoarthritis (human and veterinary).  \n  - **Key Data**: Pilot clinical data shows pain reduction in hand/knee OA vs. COX-2 inhibitor alone.  \n  - **Strategic Fit**: Expands Paradigm\u2019s OA portfolio beyond injectable PPS (Phase 3 Zilosul\u00ae).  \n  - **Financial Terms**:  \n    - Upfront: AUD $500,000 cash.  \n    - Milestones: Up to AUD $16M (e.g., AUD $5M on FDA approval).  \n  - **IP**: Granted patents in US, UK, AU; pending in EU, CA, NZ.  \n\n- **Development Focus**:  \n  - Near-term: Veterinary applications (oral formulation).  \n  - Long-term: Human trials (post-Zilosul\u00ae Phase 3).  \n\n*No material capital raising, trading halt, or liquidity impact identified.*",
  "usage": {
    "prompt_tokens": 4394,
    "completion_tokens": 236,
    "total_tokens": 4630,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-06-25T22:38:41.105108"
}